Is Avxl a buy?

The high price target for AVXL is $40.00 and the low price target for AVXL is $20.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of “Buy.”

Why is anavex up today?

Shares of biopharma outfit Anavex Life Sciences (NASDAQ:AVXL) are up 17.2% as of early afternoon following a trial update for its flagship therapy ANAVEX 2-73. The drug, also called blarcamesine, prompted marked improvements in the cognitive capabilities of Parkinson’s disease patients.

Where is anavex located?

New York, NY
Overview Suggest Edit

Type	Public
Founded	2006
HQ	New York, NY, US
Website	anavex.com

What does anavex do?

ABOUT SIGMACEPTOR. “Pharmaceutical and biopharmaceutical discovery, research and development services, namely, the discovery, research and product development of pharmaceuticals and biologic agents for the prevention and treatment of human neurological and neurodegenerative disorders, pain and cancer”.

Who makes anavex?

About Anavex Life Sciences Corp. Anavex’s lead drug candidate, ANAVEX®2-73 (blarcamesine), successfully completed a Phase 2a clinical trial for Alzheimer’s disease and recently a Phase 2 proof-of-concept study in Parkinson’s disease dementia and a Phase 2 study in adult patients with Rett syndrome.

How does Gantenerumab work?

Gantenerumab preferentially interacts with aggregated brain Aβ, both parenchymal and vascular. The antibody elicits phagocytosis of human Aβ deposits in AD brain slices co-cultured with human macrophages. It also neutralizes oligomeric Aβ42-mediated inhibitory effects on long-term potentiation in rat brains.

What is the cause of Aria?

Amyloid-related imaging abnormalities (ARIA) have been reported in Alzheimer’s disease (AD) patients treated with bapineuzumab, a humanized monoclonal antibody to amyloid-β. ARIA includes MRI signal abnormalities suggestive of vasogenic edema and sulcal effusions (ARIA-E) and hemosiderin deposits (ARIA-H).

What kind of company is ANAVEX life sciences?

Anavex®Life Sciences Corp. (the “Company”) is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including drug candidates to treat Alzheimer’s disease, other central nervous system (“CNS”)…

What kind of diseases are Anavex life sciences developing?

The Company’s lead compound ANAVEX®2-73 is being developed to treat Alzheimer’s disease, Parkinson’s disease and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome. Anavex®Life Sciences’ lead drug candidate, ANAVEX®2-73, recently completed successfully a Phase 2a clinical trial for Alzheimer’s disease.

What can Anavex life sciences do for Alzheimer’s disease?

Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. It has also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy and others.

What are the clinical trials for ANAVEX2-73?

The Company is in preparation for ANAVEX®2-73 for a Phase 2/3, placebo-controlled trial in Alzheimer’s disease as well as a Phase 2, placebo-controlled trial in Rett syndrome, for which the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) for ANAVEX®2-73 and a Phase 2, placebo-controlled trial in Parkinson’s disease. .